Mauldin Economics

Dear Tech Digest Reader,

Today, my son Ian and I are attending the first full day of the World Stem Cell Summit (WSCS), which takes place at the Hyatt Regency’s conference center here in Miami. This is kind of a home game for me—I didn’t even have to book a hotel room for the night.

The summit stretches over three days—plus last night’s plenary super session, “Changing Modern Medicine,” to kick off the event—and is a virtual Who’s Who of world-renowned biotech researchers and company executives.

But that’s not why Ian and I are going.

First and foremost, we’re here to meet with Dr. Michael West, CEO of our TransTech Alert portfolio stock BioTime (*read disclosure below) and its subsidiary AgeX, and hear his presentation.

He’ll be part of a plenary session entitled, “Stem Cell Innovations That Will Change the World.” On the same panel, we’ll see Aubrey de Grey, whom you might remember as a guest in our recent 4-part video series, “Riding the Gray Tsunami.” Aubrey serves as vice president of New Technology Discovery at AgeX.

If you’ve been a Tech Digest reader for any length of time, you’ve heard me talk about BioTime many times, and for good reason.

Even though I don’t like to play favorites, I would say this is easily the most promising company in our portfolio... and in 2017, the news coming out of BioTime and AgeX has been truly spectacular.

I’m hoping in the plenary session, Mike West will further elaborate on the progress AgeX is making with its potentially game-changing iTR (induced tissue regeneration) research.

By the way, my team and I still rate BioTime as a “buy,” so if you want to put some money into this first-class stock, it’s not too late yet. The shares have pulled back a bit recently, so you’ll probably be able to get a good entry price.

I don’t expect to sell the stock anytime soon. Many investors believe just because biotech stocks are notoriously volatile, that they are some kind of get-rich-quick scheme.

Nothing could be further from the truth. Moving through the different stages of clinical trials can take years.

However, it is true that at every stage, successful testing can drive up stock prices literally overnight—often by 100% or 200%, or more.

Breaking news of a successful trial or new information coming to light often calls for fast, immediate action. There’s absolutely no way I could make my subscribers wait a whole month to adjust their strategy.

For that reason, the premium TransTech Alert service consists of three components:

The monthly newsletter with new analysis, a thoroughly vetted stock recommendation, and detailed portfolio updates.
The weekly update, published on Thursdays, to keep you in the loop in between monthly issues.
Infrequent trade alerts that my team and I send out whenever a fast-moving stock requires immediate action—usually taking profits or selling.

So, if you want to be among the first to learn about Mike’s presentation at the World Stem Cell Summit—plus regular updates on BioTime, AgeX, and all the other stocks in our portfolio—I invite you to join the TransTech Alert family today.

I’m not exaggerating when I say this is easily the best-informed group of people when it comes to anti-aging and life-extension research outside of the biotech community.

For three days only, we’re offering 1- and 2-year subscriptions to TransTech Alert at a substantial “Summit Discount” (up to 67%).

Plus, you can claim your own “transformational package” of five valuable bonuses:

	Our acclaimed 4-part video series, “Riding the Gray Tsunami”
	My book The Methuselah Effect in ebook format
	Transformational Investing, a special report containing all the details on five must-own biotech stocks
	Exclusive access to a video of a SIC 2017 biotech panel session with Dr. Mike West
	A recording of a recent Q&A conference call with me and Mauldin Economics Chief Analyst Robert Ross

Click here to get started (this page also gives you all the details on the offer and the bonuses).

But hurry, this offer expires this Thursday, January 25.

Sincerely,

Patrick Cox
Editor, Transformational Technology Alert

*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.